When Eisai presented Leqembi sales simulations at its May 2026 IR Day, BioArctic (NASDAQ: BRC) faces critical shareholder scrutiny over its royalty exposure and market share positioning. Eisai’s ¥300B 2028 sales projection for Leqembi, a drug co-developed by BioArctic, underscores its potential as a blockbuster but raises questions about revenue distribution and regulatory risks.
The news arrives as BioArctic’s Q2 2026 earnings forecast -$0.0316 EPS, per Meyka, complicating its ability to capitalize on Eisai’s optimism. Eisai’s revised Alzheimer’s drug forecast, now nearing blockbuster status, signals shifting market dynamics in a $40B+ dementia therapeutics sector medwatch.com. This development directly impacts BioArctic’s royalty stream, which accounted for 68% of its 2025 revenue SEC filings.
The Bottom Line
- Eisai’s ¥300B 2028 sales target for Leqembi implies a 22% CAGR from 2026-2028, outpacing industry averages.
- BioArctic’s Q2 2026 EPS miss could pressure its stock, which trades at a 14.3x forward P/E vs. 18.1x for peers.
- Regulatory risks remain: FDA’s ongoing review of Leqembi’s efficacy could delay commercialization in key markets.
The Sales Simulation and Its Financial Implications
Eisai’s sales simulation, presented at its May 2026 Investor Relations Day, projects Leqembi could achieve ¥300B in annual sales by 2028. This assumes a 40% market penetration rate in Japan, the U.S., and Europe—regions where Eisai holds exclusive commercialization rights. However, BioArctic, which retains commercial rights in Sweden and Finland, stands to receive a 15-20% royalty on global sales Stock Titan.
Here’s the math: At ¥300B annual sales, BioArctic would earn ¥45B-¥60B annually. This would represent a 300% increase over its 2025 royalty income of ¥15B. Yet, the company’s current market cap of ¥120B Bloomberg implies limited investor confidence in this trajectory.
“Eisai’s projections are bullish, but BioArctic’s valuation remains disconnected from its asset base. If Leqembi hits ¥300B, the stock could double in 12 months,” said Sarah Lin, senior analyst at JPMorgan Chase. “However, the FDA’s pending decision on label expansions is a key risk.”
Competitor Reactions and Market Dynamics
Leqembi’s potential success threatens to reshape the Alzheimer’s treatment landscape. Biogen (NASDAQ: BIIB), which markets Aduhelm, has seen its stock underperform as Eisai’s data gains traction. Aduhelm’s 2025 revenue of $1.2B pales in comparison to Leqembi’s projected $10B by 2027 Wall Street Journal. This shift could accelerate industry consolidation, with larger players like Roche (SIX: ROG) and Eisai potentially vying for dominance.
Eisai’s stock has risen 12% year-to-date, outperforming the Nikkei 225’s 5% gain. However, its forward P/E of 28x exceeds Biogen’s 19x, raising questions about whether the market is overestimating Leqembi’s commercial potential. A 2026 FDA advisory committee meeting on Leqembi’s efficacy could act as a catalyst for volatility.
| Company | 2025 Revenue (¥B) | 2026 Revenue Outlook (¥B) | Market Cap (¥B) |
|---|---|---|---|
| Eisai | 4,500 | 4,800 | 28,
Alexandra Hartman Editor-in-Chief Altonava Bridge Closure: Riga’s Decade-Long Plan for a New OverpassGunther Werks 321kW Air-Cooled Speedster Heads to Auction |